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ABSTRACT 
Purpose: Pre-participation health screening is recommended to detect individuals susceptible 
to serious adverse cardiovascular complications during exercise. Although expert opinion and 
best available scientific evidence have informed recent modifications, there remains limited 
experimental data to support or refute current practice. We therefore aimed to quantify the 
impact of change to the ACSM pre-participation health screening guidelines on risk 
classification and referral for medical clearance in a large cohort of undergraduate university 
students. Methods: Participants attended the laboratory on a single occasion to undergo pre-
participation health screening. Information concerning health status was obtained via self-
report questionnaire and objective physiological assessment with all data recorded 
electronically and evaluated against ACSM screening guidelines (9th and 10th Edition). Results: 
Five-hundred and fifty-three students completed the study. The 9th Edition screening guidance 
resulted in eighty-two (15%) subjects classified as high-risk, almost one quarter (24%) 
classified as moderate-risk, and almost two-thirds (61%) classified as low-risk. In comparison, 
the updated 10th Edition screening guidance resulted in a significant reduction in those 
previously classified as either high-risk (5%) or moderate risk (2%), respectively. The majority 
of subjects (93%) were therefore cleared to begin a structured exercise programme. Taken 
together, approximately one-third (32%) fewer medical referrals were required when applying 
the updated 10th Edition guidance (χ2 (4) = 247.7, P<0.001). Conclusion: The updated ACSM 
10th Edition pre-participation screening guidance reduces medical referrals by approximately 
one-third. These findings are in keeping with previous reports and thus serve to consolidate and 
justify recent modification - particularly when applied to young adult or adolescent populations. 
The findings and arguments presented should be used to refine and inform future guidance. 
Key words: ACSM, Exercise, Health, Physical Activity, Pre-participation, Screening.
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INTRODUCTION 1 
Regular physical activity and structured exercise training are widely accepted to promote health 2 
and well-being in addition to lowering the risk of developing chronic disease such as 3 
cardiovascular disease (CVD), diabetes mellitus and cancers across the lifespan (1). However, 4 
despite recognition of health benefit (i.e. reduced morbidity and mortality) (2), a large 5 
proportion (~30%) of the global population remain sedentary (3, 4). On this basis, and to reduce 6 
healthcare costs attributed to sedentary living (5), the World Health Organisation (WHO) have 7 
recently targeted a reduction in physical inactivity over the next decade as a key global health 8 
priority (6-9).  9 
The American College of Sports Medicine (ACSM) currently advise completing at least 30 10 
minutes of moderate intensity activity 5 days per week, or 20 minutes of vigorous intensity 11 
activity 3 days per week to optimise and maintain health (10). However, prior to initiating an 12 
exercise programme, irrespective of age, it is recommended that pre-participation health 13 
screening is conducted to detect individuals susceptible to serious adverse cardiovascular 14 
complications; i.e. sudden cardiac death and/or acute myocardial infarction during or post 15 
exercise (10). 16 
Historically, pre-participation health screening, as described in the 9th Edition and previous 17 
versions of the ACSM Guidelines to Exercise Testing and Prescription focused on: (a) risk 18 
stratification calculated according to CVD risk factors and (b) the presence of signs or 19 
symptoms of and/or history of cardiovascular, pulmonary, renal, liver or metabolic disease. 20 
This approach permitted recommendations concerning suitability to commence exercise or the 21 
requirement for further clinical assessment (i.e. referral to a physician to obtain medical 22 
clearance) (11). 23 
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More recently, however, it has been acknowledged that employing this approach may 24 
contribute to excessive medical referrals thereby placing unnecessary burden on healthcare 25 
infrastructure, and equally, may create a barrier to physical activity and exercise engagement 26 
(12). In an attempt to simplify guidance, and address these concerns, a panel of experts 27 
convened by the ACSM published modifications to the pre-participation health screening 28 
criteria in 2015 (subsequently incorporated in the 10th Edition of the Guidelines for Exercise 29 
Testing and Prescription) (10). Accordingly, screening guidance currently centres on: (a) 30 
current level of physical activity, (b) the presence of known cardiovascular, metabolic, or renal 31 
disease (or signs or symptoms of these diseases), and (c) the desired intensity of the exercise 32 
bout / programme (10).  33 
Although expert opinion and best available scientific evidence have informed these 34 
modifications, there remains limited experimental data to support or refute current practice, 35 
particularly when applied to young adult (i.e. <40 years) or adolescent populations (13). This 36 
is important given pre-participation health screening is recommended within universities and 37 
colleges (notably across exercise science courses and sports teams), and as part of inductions 38 
to gymnasia and fitness centres around the globe.  39 
The primary aim of this study was therefore to quantify the impact and examine the implications 40 
of change to the ACSM pre-participation health screening guidelines on risk classification and 41 
referral for medical clearance in a large cohort of UK-based undergraduate university students. 42 
A secondary aim was to evaluate the requirement for widespread screening in this context by 43 
characterising the prevalence of CVD risk and signs/symptoms or history of non-communicable 44 
disease. We hypothesised that the updated 10th Edition guidance would reduce the percentage 45 
of medical referrals whilst providing a cost-effective and time-efficient approach to pre-46 
participation health screening in young adult populations.  47 
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METHODS 48 
Study population and experimental design 49 
Six-hundred and five undergraduate university sport and exercise science students were 50 
enrolled into the study between 2015-17. In accordance with the Leeds Beckett University (UK) 51 
local pre-exercise risk assessment and risk management policy, all participants attended the 52 
laboratory on a single occasion to undergo pre-participation health screening. Information 53 
concerning health status was obtained via self-report questionnaire and objective physiological 54 
assessment with all data recorded electronically. In accordance with ACSM 9th Edition 55 
guidance (described below) - a finger-prick capillary blood sample was obtained for the 56 
assessment of blood glucose and total cholesterol for subjects who presented with 1 CVD risk 57 
factor. All testing was conducted by trained personnel and evaluated against ACSM pre-58 
participation screening guidelines (9th and 10th Edition). Data were analysed retrospectively by 59 
two independent reviewers (OP and AS) to complete risk classification and determine screening 60 
outcome. All tests and procedures were approved by the local research ethics committee (IRB 61 
ethics ID: 50858) and all subjects provided written informed consent (Figure 1). 62 
Pre-participation health screening guidance  63 
9th Edition 64 
The ACSM 9th Edition algorithm classifies individuals according to risk; i.e. low, moderate, 65 
and high. Screening outcome is determined based on the sum of CVD risk factors; i.e. age, 66 
family history of heart disease, smoking status, physical activity, obesity (based on BMI and/or 67 
waist circumference), dyslipidaemia, dysglycaemia and resting blood pressure values, and 68 
presence or absence of signs or symptoms, or known cardiovascular, pulmonary, renal, liver or 69 
metabolic disease with recommendations for medical clearance based on the desired intensity 70 
of exercise (Figure 2A). 71 
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10th Edition 72 
The ACSM 10th Edition algorithm classifies individuals as physically active or inactive 73 
according to the level of exercise or physical activity engagement over the past 3 months 74 
(defined as planned, structured physical activity of at least 30 min duration at moderate intensity 75 
on at least 3 days per week). Screening outcome is determined based on presence or absence of 76 
known cardiovascular, metabolic, or renal disease and presence or absence of signs or 77 
symptoms of these conditions with recommendations for medical clearance based on the 78 
desired intensity of exercise (Figure 2B). 79 
Risk stratification and screening outcome (9th vs. 10th Edition) 80 
To allow a direct comparison of guidance, risk stratification and screening outcome was 81 
classified as (a) low-risk (colour code: green) (i.e. medical clearance not necessary), (b) 82 
moderate-risk (colour code: yellow) (i.e. medical clearance only required for vigorous 83 
exercise), (c) high-risk (colour code: red) (i.e. medical clearance recommended prior to any 84 
physical activity) (Figure 2).  85 
Statistical analysis 86 
Referral percentages were calculated and stratified with cross-tabulation conducted to compare 87 
screening outcome. Independent t-tests (continuous variables) and Chi-squared tests 88 
(categorical variables) were employed to evaluate between group (sex) differences. All other 89 
data were reported descriptively according to prevalence of CVD risk factors, signs and 90 
symptoms of disease and prior history of non-communicable disease. Data were analysed using 91 
SPSS Statistics statistical software package Version 24 (SPSS Inc., Chicago, IL). P<0.05 was 92 
considered statistically significant. Data are reported as mean ± SD unless otherwise stated. 93 
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RESULTS 94 
Study population 95 
Of the 605 subjects recruited to this study, 553 (male n = 393) completed the study, while 52 96 
(male n = 43) were excluded from the analysis due to incomplete datasets. Subjects’ clinical 97 
characteristics are presented in Table 1.  98 
Comparison of risk stratification and screening outcome 99 
The 9th Edition screening guidance resulted in eighty-two (15%) subjects classified as high-100 
risk, one-hundred and thirty five (24%) classified as moderate-risk, and three hundred thirty 101 
three (61%) classified as low-risk. In comparison, the updated 10th Edition screening guidance 102 
resulted in twenty-seven classified as high-risk (5%) and thirteen classified as moderate risk 103 
(2%), respectively. All subjects originally classified as moderate risk according to 9th Edition 104 
guidance were re-classified as low risk when applying the 10th Edition guidance. The remaining 105 
five hundred and thirteen (93%) were therefore cleared to begin a structured exercise 106 
programme in accordance with the 10th edition of the ACSM’s Guidelines for Exercise Testing 107 
and Prescription. Taken together, almost one-third (32%) fewer medical referrals were required 108 
when applying the updated 10th Edition guidance (χ2 (4) = 247.7, P<0.001) (Figure 3A).  109 
High-risk re-classification 110 
Of the eighty-two subjects (15% of all participants) originally classified as high-risk, twenty-111 
seven (5%) remained the same and required referral for medical clearance due to a sign and/or 112 
symptom of cardiovascular, metabolic or renal disease. Thirteen subjects (16%) were re-113 
classified as moderate risk due to being physically active and having known cardiovascular, 114 
metabolic or renal disease but also being asymptomatic. Forty-two subjects (51%) were re-115 
classified as low-risk due to guidance modification concerning pulmonary and liver (Figure 116 
3B). Specifically, thirty-eight subjects (46%) diagnosed with asthma, one subject (1%) 117 
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diagnosed with cystic fibrosis, one subject (1%) diagnosed with interstitial lung disease, and 118 
two subjects (2%) diagnosed with liver disease were reclassified as low-risk (Table 2). 119 
CVD risk factors, signs and/or symptoms and history of disease 120 
Prevalence of family history of CVD, physical inactivity, obesity (based on BMI and waist 121 
circumference thresholds), dyslipidaemia and dysglycaemia were not different between sexes 122 
(P>0.05). In contrast, smoking status (χ2 (1) = 9.172, p=0.002) and evidence of hypertension 123 
(χ2 (1) = 5.995, p=0.014) were higher in males. Descriptive statistics and prevalence data for 124 
CVD are provided in Table 3. Signs and/or symptoms of disease were not different between 125 
sexes (P>0.05). For the majority of diseases, no difference was observed between sexes 126 
(P>0.05). Descriptive statistics and prevalence data for signs and/or symptoms and history of 127 
non-communicable disease are provided in Table 2.  128 
Blood sample analysis (n = 135) 129 
One hundred and thirty-five subjects (male: n = 102) (24%) presented with 1 CVD risk factor 130 
and therefore provided a capillary blood sample in accordance with 9th Edition screening 131 
guidance. Of these, only five subjects (4%) presented with dyslipidaemia and only two subjects 132 
(1%) presented with dysglycaemia. In contrast, the other one hundred and twenty-eight subjects 133 
(95%) (1 CVD risk factor) were confirmed as low-risk following determination of normal 134 
resting blood lipid and glucose profiles (Table 3).135 
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DISCUSSION 136 
In support of our hypothesis, the present study provides the first experimental evidence to 137 
confirm that when employing the revised ACSM 10th Edition pre-participation screening 138 
guidance, almost one-third (32%) fewer university students were referred for medical 139 
clearance. The implications of our findings can be considered two-fold: firstly, reducing the 140 
impact of unnecessary or excessive medical referrals on primary healthcare infrastructure (i.e. 141 
cost, time and resource), and secondly, reducing barriers to exercise and physical activity 142 
engagement. The latter is of particular importance given the strong association between 143 
exercise engagement in early life and physical activity status across the lifespan (14). 144 
The majority of research to date investigating pre-participation health screening has primarily 145 
evaluated individuals considered to be at ‘heightened’ risk of cardiovascular complications 146 
during exercise (i.e. mid-adult or elderly age-groups) (13, 15). For example, a recent 147 
retrospective analysis by Whitfield and colleagues compared referral patterns between the 148 
ACSM 10th Edition guidance with previously validated (and widely implemented) pre-149 
participation questionnaires (i.e. AAPQ and PAR-Q) in a large representative sample (n = 150 
6785) of United States adults (13). Similar to the present study, it was found that the 10th 151 
Edition guidance resulted in significantly fewer (~38%) medical referrals. The sample size of 152 
this comparative analysis is clearly a study strength, however it is important to acknowledge 153 
that several symptoms contributing to the ACSM guidance were not assessed, with all adults 154 
aged 40-years or older (13). 155 
In contrast to this approach, for the first time, our study provides a direct comparison of 156 
screening methods (i.e. ACSM 9th vs. 10th Edition) applicable to younger age-groups (i.e. 157 
young adult and adolescent populations). It is our view, that the data from the present study 158 
should therefore be interpreted to consolidate previous findings and interpreted to support 159 
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recent modification and inform potential revisions to future ACSM guidance. Taken together, 160 
the simplicity, cost-effectiveness and short time-frame to complete and obtain a screening 161 
outcome when applying the 10th Edition guidance provides strong justification to employ 162 
widespread screening (irrespective of age) prior to beginning an exercise programme.  163 
The lower proportion of referrals and change to screening outcome in the present study is 164 
attributable to guidance modification concerning: (a) evaluating physical activity engagement, 165 
(b) removal of pulmonary and liver disease from screening outcome, and (c) discounting CVD166 
risk factors (10). Of the eighty-two subjects that were originally classified as high-risk 167 
according to 9th Edition guidance, twenty-seven (15%) remained unchanged due to reporting 168 
a sign and/or symptom of cardiovascular, metabolic or renal disease. However, thirteen (16%) 169 
(presenting with known cardiovascular, metabolic or renal disease and asymptomatic) were re-170 
classified to moderate risk due to physical activity either meeting or exceeding current 171 
recommendations (10). As the absolute and relative risks of acute cardiovascular events during 172 
exercise are known to be very low in asymptomatic individuals (16-18), re-classification and 173 
clearance to begin moderate intensity exercise (40-60% aerobic capacity) is certainly logical 174 
when applied to physically active individuals (irrespective of disease status). 175 
It is important to note that self-report physical activity data acquired through consultation and 176 
questionnaire has previously been reported to provide poor validity and reliability when 177 
compared to device-based measures of human movement (e.g. pedometers and accelerometers 178 
etc.) (19). Indeed the most comprehensive appraisal of the literature to date concluded that self-179 
report frequently results in both an over and under-estimation of physical activity (20). These 180 
findings therefore have important ramifications for risk assessment when employing 10th 181 
Edition guidance in the context of health screening and exercise prescription. Although the 182 
prominence of physical activity in the 10th Edition positively contributes to the observed 183 
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reduction in medical referrals, limitations associated with self-report should be considered 184 
during consultation. To optimise the accuracy of estimated daily physical activity, what 185 
constitutes ‘planned, structured physical activity’ should be clearly defined, and it is our view 186 
that supplementary or follow-up questions should be considered and encouraged moving 187 
forward.  188 
The decision to no longer automatically refer those with pulmonary disease had a significant 189 
impact on screening outcome. As evidenced by our findings, of those previously classified as 190 
high-risk, almost half (49%) were re-classified as low-risk when discounting pulmonary 191 
disease (asthma: 95%, cystic fibrosis: 2.5% and interstitial lung disease: 2.5%). In support of 192 
this modification, it is worth noting that pulmonary disease is not associated with an increased 193 
risk of cardiovascular complications during exercise, rather, long-term physical inactivity, due 194 
to fear of provoking exertional breathlessness or exacerbation, is more likely to increase the 195 
relative-risk of an adverse cardiovascular event in this population (21). The overall prevalence 196 
of asthma (~7%) in our cohort is in keeping with current UK estimates (~8%) (22). It is 197 
important to acknowledge however that asthma is a complex disease consisting of several 198 
variants with unique underlying pathophysiology (23). In the context of pre-participation health 199 
screening, asthma sub-type and clinical control status should also be considered before granting 200 
clearance to commence vigorous or maximal intensity exercise. Caution is therefore advised 201 
when screening individuals predisposed to exercise-induced asthma, or those with severe, 202 
uncontrolled, or difficult to treat airways disease (24). Irrespective of this recommendation, the 203 
reduced referral pattern should help to deter physical inactivity in pulmonary disease patients. 204 
Indeed, the importance of regular exercise and physical activity in the context of pulmonary 205 
rehabilitation is well-established (25, 26). 206 
12 
Perhaps unsurprisingly liver disease was only found to have a minor impact on screening 207 
outcome in our young adult population. However, considering the growing global epidemic of 208 
obesity and associated metabolic disease (largely attributed to modifiable lifestyle factors such 209 
as diet, alcohol consumption, and physical inactivity), it is likely that a similar reduction in 210 
referral proportions related to liver disease would be observed when applied to older or ageing 211 
populations (27). Similarly, for the most part, the prevalence of CVD risk factors in our cohort 212 
was relatively low (<5%) with no difference observed between sexes.  213 
The suggestion of excessive referrals in the past is supported by our data given the majority of 214 
our population (95%) who presented with 1 CVD risk factor (following the screening 215 
questionnaire and measurements of anthropometry and resting blood pressure) returned to low-216 
risk following blood analysis (i.e. normal resting blood glucose and lipid profiles). Of concern, 217 
the incidence of smoking status (9%) and evidence of hypertension (14%) was high in males, 218 
which clearly has ramifications for long-term respiratory health (28) and the development of 219 
CVD and heightened relative risk of mortality in later life (29). Finally, the incidence of signs 220 
and/or symptoms or history of non-communicable disease was low when compared against 221 
current estimates from the global population (30). 222 
Methodological considerations and future research  223 
Despite our encouraging findings, it is important to recognise and consider potential limitations 224 
to the updated 10th Edition guidance. For example, current policy stipulates clearance to engage 225 
in ‘vigorous intensity exercise’ defined as 60% aerobic capacity. Whilst evidence indicates 226 
that the absolute risk of cardiovascular complications during high-intensity exercise is low, the 227 
relative risk of sudden cardiac death and/or acute myocardial infarction during or post exercise 228 
increases (irrespective of age, current physical fitness or functional capacity) when 229 
approaching maximal exercise. To further mitigate risk; in circumstances where individuals 230 
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are required to exercise to volitional exhaustion (e.g. maximal oxygen uptake testing), it may 231 
be pragmatic to evaluate the accuracy of self-report information relevant to screening outcome 232 
(e.g. physical activity status) on a case-by-case basis before granting clearance. Although we 233 
recognise that ACSM pre-participation health screening guidelines are designed to detect 234 
individuals susceptible to serious adverse cardiovascular complications, it is also important to 235 
consider and rule-out other relevant conditions that may be made worse or increase the risk of 236 
injury during exercise. In support of this concept, musculoskeletal injury was reported in 237 
approximately 12% our cohort which would have remained undetected without requesting 238 
further patient history. Finally, as with all screening criteria, a potential for false-positive or 239 
false-negative outcome exists when employing current guidance. To provide evidence-based 240 
recommendations and to justify benefit of widespread pre-participation health screening, 241 
validation against objective diagnostic work-up in those referred for medical clearance, and 242 
long-term follow-up of individuals cleared to exercise remains a research priority.  243 
Conclusion 244 
In summary, in a large cohort of UK-based undergraduate university students, we have 245 
demonstrated that the ACSM 10th Edition guidance reduces medical referrals by 246 
approximately one-third. These findings are in-keeping with previous reports and thus serve to 247 
consolidate and justify recent modification - particularly when applied to young adult or 248 
adolescent populations. In order to continue to optimise the health, well-being and overall 249 
safety of individuals engaging in exercise, consideration of the findings and arguments 250 
presented should be used to refine and inform future guidance. 251 
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TABLE FOOTNOTES 252 
253 
Table 1. Subject clinical characteristics. 254 
Table 2. Signs and symptoms and history of non-communicable disease (ACSM 9th and 10th 255 
Edition). 256 





FIGURE LEGENDS 261 
Figure 1. Schematic detailing experimental design. 262 
ACSM 9th Edition: 
*CVD risk factors
Age: men >45 years; women>55 years
Family history: myocardial infarction, coronary revascularisation, or sudden death before 55 year in father or other male first-degree
relative or before 65 year in mother or other female first-degree relative
Cigarette smoking: Current cigarette smoker or those who quit within the previous 6-months or exposure to environmental tobacco
smoke
Sedentary lifestyle: Not participating in at least 30 min of moderate intensity, physical activity (40% - <60% VO2R) on at least 3 day
of the week for at least 3 months
Obesity: Body mass index ≥30kg.m2 or waist circumference >102cm for men and >88cm for women
Hypertension: Systolic blood pressure ≥140mmHg and/or diastolic ≥90mmHg, confirmed by measurements on at least two separate
occasions, or on anti-hypertensive medication
Dyslipidaemia: Low-density lipoprotein (LDL) cholesterol ≥130mg.dL-1 (3.37mmol.L-1) or high-density lipoprotein (HDL)
cholesterol <40mg.dL (1.04 mmol.L-1) or on lipid-lowering medication. If total serum cholesterol is all that is available, use
≥200mg.dL-1 (5.18 mmol.L-1)
Prediabetes: Impaired fasting glucose = fasting plasma glucose ≥100mg.dL-1 (5.55mmol.L-1) and ≤125mg.dL-1 (6.94 mmol.L-1) or
impaired glucose tolerance test = 2 hour values in oral glucose tolerance test ≥140mg.dL-1 (7.77 mmol.L-1) and ≤199mg.dL-1
(11.04mmol.L-1) confirmed by measurements on at least two separate occasions.
Negative risk factors: High-density lipoprotein cholesterol ≥60mg.dL-1 (1.55mmol.L-1)
**Signs or symptoms of disease 
Pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from ischemia 
Shortness of breath at rest or with mild exertion 
Dizziness of syncope 
Orthopnoea or paroxysmal nocturnal dyspnoea  
Ankle oedema  
Palpitations or tachycardia 
Intermittent claudication 
Known heart murmur 
Unusual fatigue or shortness of breath with usual activities 
***History of disease 
Cardiovascular: Cardiac, peripheral vascular, or cerebrovascular disease 
Pulmonary: Chronic obstructive pulmonary disease, asthma, interstitial lung disease or cystic fibrosis 
Metabolic: Diabetes mellitus (types 1 and 2) or renal disease 
ACSM 10th Edition: 
†Participates in regular exercise 
Performing planned, structured physical activity at least 30 min at moderate intensity on at least 3 days per week for at least the last 
3 months 
††Signs or symptoms of disease 
At rest or during activity; includes pain, discomfort in the chest, neck, jaw, arms, or other areas that may result from ischemia; 
shortness of breath at rest or with mild exertion; dizziness or syncope; orthopnoea or paroxysmal nocturnal dyspnoea; ankle oedema; 
palpitations or tachycardia; intermittent claudication; known heart murmur; or unusual fatigue or shortness of breath with usual 
activities 
†††History of disease 
Cardiac, peripheral vascular, or cerebrovascular disease 








Figure 3A. Screening outcome according to 9th and 10th Edition ACSM pre-participation 269 
health screening guidance.  270 
271 
ACSM 9th Edition: red - medical clearance recommended (n = 82; 15%); yellow - medical clearance required for vigorous 
intensity exercise only (n = 135; 24%); green - medical clearance not required (n = 333; 61%). 
ACSM 10th Edition: red - medical clearance recommended (n = 27; 5%); yellow - medical clearance required for vigorous 
intensity exercise only (n = 13; 2%); green - medical clearance not required (n = 513; 93%) 
272 
Figure 3B. Re-classification of high-risk individuals (n = 82) according to updated pre-273 
participation health screening guidelines (ACSM 10th Edition).  274 
ACSM 10th Edition: red - medical clearance recommended (n = 27; 33%); yellow - medical clearance required for vigorous 







Medical clearance: Approval from a healthcare professional to engage in exercise 
Mod ex: Moderate intensity exercise; 40% - <60% VO2R; 3 - <6 METS “An intensity that causes noticeable increases in heart rate and 
breathing” 
Vig ex: Vigorous intensity exercise; 60% VO2R; 6 METS. “An intensity that causes substantial increases in heart rate and breathing” 
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